| Indoleamine 2, 3-dioxygenase (IDO) inhibitors and cancer immunotherapy Y Fujiwara, S Kato, MK Nesline, JM Conroy, P DePietro, S Pabla, ... Cancer treatment reviews 110, 102461, 2022 | 90 | 2022 |
| A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy Y Fujiwara, A Mittra, AR Naqash, N Takebe Cancer Drug Resistance 2020 (3), 2020 | 35 | 2020 |
| Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib N Fukuda, K Toda, Y Fujiwara, X Wang, A Ohmoto, T Urasaki, N Hayashi, ... In Vivo 34 (5), 2859-2864, 2020 | 21 | 2020 |
| Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer Y Sato, N Fukuda, Y Fujiwara, X Wang, T Urasaki, A Ohmoto, K Nakano, ... in vivo 35 (2), 1211-1215, 2021 | 17 | 2021 |
| The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report Y Fujiwara, K Ito, A Takamura, K Nagata Journal of medical case reports 12 (1), 295, 2018 | 15 | 2018 |
| Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital Y Sato, Y Fujiwara, N Fukuda, B Hayama, Y Ito, S Ohno, S Takahashi Cancer Cell, 2021 | 14 | 2021 |
| Adverse events induced by nivolumab and ipilimumab combination regimens K Somekawa, N Horita, A Kaneko, Y Tagami, N Fukuda, H Matsumoto, ... Therapeutic Advances in Medical Oncology 14, 17588359211058393, 2022 | 13 | 2022 |
| The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials Y Fujiwara, N Horita, H Namkoong, MD Galsky European Journal of Cancer 150, 168-178, 2021 | 12 | 2021 |
| Granulocyte Colony-Stimulating Factor-Associated Aortitis: Treatment Suggestion for This Complication Y Fujiwara, T Yamaguchi, M Nakane JCO Oncology Practice, 2020 Jul 9;OP2000121, 2020 | 11 | 2020 |
| Targeting KRAS: Crossroads of Signaling and Immune Inhibition S Kato, Y Fujiwara, DS Hong Journal of Immunotherapy and Precision Oncology 5 (3), 68-78, 2022 | 9 | 2022 |
| Clinical impact of cachexia in head and neck cancer patients who received chemoradiotherapy N Hayashi, Y Sato, Y Fujiwara, N Fukuda, X Wang, K Nakano, T Urasaki, ... Cancer management and research, 8377-8385, 2021 | 9 | 2021 |
| Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review A Obeidat, K Silangcruz, L Kozai, E Wien, Y Fujiwara, Y Nishimura Journal of Immunotherapy, 10.1097, 2022 | 8 | 2022 |
| Screening for COVID-19 in symptomatic cancer patients in a cancer hospital Y Fujiwara, Y Sato, X Wang, K Oikado, Y Sato, N Fukuda, T Enokida, ... Cancer Cell 38 (5), 609-610, 2020 | 7 | 2020 |
| Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials Y Fujiwara, N Horita, M Harrington, H Namkoong, H Miyashita, MD Galsky Cancer Immunology, Immunotherapy 71 (12), 2837-2848, 2022 | 6 | 2022 |
| Self‐assessment of health status among lesbian, gay, and bisexual cancer survivors in the United States Y Li, N Theodoropoulos, Y Fujiwara, H Xie, Q Wang Cancer 127 (24), 4594-4601, 2021 | 6 | 2021 |
| A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification … S Minomo, Y Fujiwara, S Sakashita, A Takamura, K Nagata Journal of Medical Case Reports 15, 1-7, 2021 | 6 | 2021 |
| Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review … Y Fujiwara, N Horita, E Adib, S Zhou, AH Nassar, ZULA Asad, A Cortellini, ... The Lancet Oncology, 2024 | 5 | 2024 |
| Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients N Fukuda, M Yunokawa, Y Fujiwara, X Wang, A Ohmoto, N Hayashi, ... Cancer Reports 4 (2), e1322, 2021 | 5 | 2021 |
| Tumor Growth Rate as a Prognostic Factor for Metastatic or Recurrent Adenoid Cystic Carcinoma of the Head and Neck Patients Treated with Carboplatin Plus Paclitaxel N Fukuda, Y Fujiwara, X Wang, A Ohmoto, T Urasaki, N Hayashi, Y Sato, ... | 5 | 2020 |
| Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: A systematic review and meta-analysis A Ohmoto, Y Fujiwara, N Horita, K Nakano, S Takahashi Discover Oncology 13 (1), 40, 2022 | 4 | 2022 |
